Oragenics Advances Concussion Treatment Development Through SCOPE Summit Participation

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company, announced its participation at the SCOPE Summit 2026, the 17th annual Summit for Clinical Ops Executives organized by the Cambridge Healthtech Institute. The company plans to engage with leaders across biopharma, clinical research, regulatory affairs, and clinical technology as it advances its proprietary intranasal delivery platform and prepares for a Phase 2a clinical trial in Australia of ONP-002, its therapeutic candidate for concussion and mild traumatic brain injury. This development is significant because concussion and mild traumatic brain injury represent areas with substantial unmet medical need and currently have no FDA-approved treatments available.

The company's participation in the SCOPE Summit provides an important platform for collaboration and knowledge exchange as Oragenics moves toward clinical trials. The summit brings together executives and professionals from across the clinical operations spectrum, offering opportunities for strategic partnerships and regulatory insights. Oragenics' intranasal delivery platform has potential applications across multiple neurological conditions beyond concussion, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders, positioning the company at the forefront of neurological therapeutic innovation.

ONP-002 represents a first-of-its-kind therapeutic approach for concussion treatment, utilizing intranasal delivery to target brain injuries directly. The planned Phase 2a trial in Australia will be followed by U.S. Phase 2b trials, marking critical steps in the drug development pathway. The company's technology platform addresses the challenge of delivering therapeutics across the blood-brain barrier, a significant obstacle in neurological drug development. For more information about Oragenics' developments, visit https://www.oragenics.com.

The broader implications of this announcement extend to the millions of individuals affected by traumatic brain injuries annually. Concussions represent a significant public health concern with limited treatment options currently available. Oragenics' approach could potentially transform the standard of care for these conditions if clinical trials prove successful. The company's work aligns with growing recognition of the long-term consequences of mild traumatic brain injuries and the need for effective interventions. The biotechnology sector's focus on neurological disorders continues to expand as understanding of brain function and injury mechanisms advances.

Oragenics' participation in industry events like the SCOPE Summit demonstrates the company's commitment to advancing its clinical programs through collaboration and knowledge sharing. The summit provides access to cutting-edge clinical technologies and regulatory expertise that can accelerate development timelines. As the company prepares for its Phase 2a trial, engagement with clinical operations professionals becomes increasingly important for trial design, patient recruitment, and data management. The convergence of these factors positions Oragenics to potentially address a significant gap in neurological care through innovative therapeutic approaches.